Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PTAFR Antibodies:
anti-Mouse (Murine) PTAFR Antibodies:
anti-Rat (Rattus) PTAFR Antibodies:
Go to our pre-filtered search.
Human Polyclonal PTAFR Primary Antibody for IF (p), IHC (p) - ABIN687127
Hammond, Lu, Gelbard: Platelet Activating Factor Enhances Synaptic Vesicle Exocytosis Via PKC, Elevated Intracellular Calcium, and Modulation of Synapsin 1 Dynamics and Phosphorylation. in Frontiers in cellular neuroscience 2016
we demonstrate that PAFR inhibition can selectively enhances the sensitivity of radiotherapy in prostate cancer cells with elevated PAFR expression after irradiation exposure
PAFR overexpression is associated with pneumococcal infection.
WEB-2086 represents an innovative class of candidate drugs for inhibiting PAFr-dependent lung infections caused by the main bacterial drivers of smoking-related COPD (show ARCN1 Antibodies).
PAF (show KIAA0101 Antibodies) stimulation dose-dependently promoted the invasion, migration and growth of prostate cancer cells in vitro, while knockdow our findings demonstrate that PAFR can activate ERK1/2 (show MAPK1/3 Antibodies) pathway, and subsequently increase MMP-3 (show MMP3 Antibodies) expression and decrease E-cadherin (show CDH1 Antibodies) expression
PAFR is overexpressed in NSCLC as well as in breast, colorectal, and gastric carcinomas. PAFR expression correlates with clinical stages, survival time, and distant metastasis. PAF (show KIAA0101 Antibodies)/PAFR signaling also upregulated IL6 (show IL6 Antibodies) expression and STAT3 (show STAT3 Antibodies) activation.
we made the first demonstration that dysregulation of PAFR and the positive regulatory loop between PAFR and pAKT (show AKT1 Antibodies) contribute to malignant progression of esophageal squamous cell carcinoma
Data support an important role for PAFR in tumor growth and suggest that engagement of PAFR interferes with selected pathways in macrophages, changing their phenotype into that of a regulatory with suppressor activities. [review]
Epithelial PAFr expression is upregulated in smokers, especially in those with COPD (show ARCN1 Antibodies), and is not obviously affected by inhaled corticosteroid therapy.
Results suggest that WEB2086 and AG1478 are synergistic in ovarian cancer cells with high expression of both platelet-activating factor receptor (PAFR) and epidermal growth factor receptor (EGFR (show EGFR Antibodies)).
PAFR may have an important role in modulating the cisplatin sensitivity of ovarian cancer cells.
Results show that CD36 (show CD36 Antibodies) and Platelet-Activating Factor Receptor are important mediators of house dust mites (HDM (show HDAC3 Antibodies)) allergy development and that inhibiting HDM (show HDAC3 Antibodies) engagement with phosphorylcholine receptors in the lung protects against allergic airway disease.
Study demonstrated that PAFR has a compelling involvement in Brucella abortus uptake as a promoter of phagocytosis, which is associated with JAK2 (show JAK2 Antibodies) signaling activation.
In the absence of PAFR signalling, monocytes and macrophages acquire a pro-inflammatory phenotype, resulting in adipose tissue inflammation and metabolic dysfunction.
Data (including data from studies in knockout mice) suggest that signal transduction via platelet-activating factor (PAF (show KIAA0101 Antibodies)) and PAF receptor is involved in regulation of lipid metabolism/inflammation in liver of mice on high-refined carbohydrate diet.
ExoU activates NF-kappaB (show NFKB1 Antibodies) by PAFR signalling, which in turns enhances PAFR expression, highlighting an important mechanism of amplification of response to this P. aeruginosa toxin.
In PAF receptor-knockout mice, diet-induced obesity is exacerbated.
Bacteria did not associate with PAFR, indicating an indirect role of PAFR in pneumococcal adhesion to endothelial cells.
PAFR deficiency resulted in less inflammation in adipose tissue and improvement in glucose homeostasis in mice fed a high-carbohydrate diet
PAFR and CD36 (show CD36 Antibodies) coimmunoprecipitated with flotillin-1 (show FLOT1 Antibodies), a constitutive lipid raft protein, and disruption of these membrane microdomains by methyl-beta-cyclodextrin reduced apoptotic cells phagocytosis
Our findings establish the existence of a functional partnership PAF-R/eNOS (show NOS3 Antibodies) on endothelial cell plasma membrane.
The gene expression of PAFR was upregulated, as an effect of light exposure, in the third eyelid but not in the cornea.
PAF (show KIAA0101 Antibodies) and luteinizing hormone signaling plays an important role in regulating the production of excessive oxidants.
The results provide clear evidence for expression of PAFr in bovine granulosa cells and its functional involvement in PAF (show KIAA0101 Antibodies)/PAFr-mediated stimulation of cell recruitment.
This gene encodes a seven-transmembrane G-protein-coupled receptor for platelet-activating factor (PAF) that localizes to lipid rafts and/or caveolae in the cell membrane. PAF (1-0-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) is a phospholipid that plays a significant role in oncogenic transformation, tumor growth, angiogenesis, metastasis, and pro-inflammatory processes. Binding of PAF to the PAF-receptor (PAFR) stimulates numerous signal transduction pathways including phospholipase C, D, A2, mitogen-activated protein kinases (MAPKs), and the phosphatidylinositol-calcium second messenger system. Following PAFR activation, cells become rapidly desensitized and this refractory state is dependent on PAFR phosphorylation, internalization, and down-regulation. Alternative splicing results in multiple transcript variants.
platelet-activating factor receptor
, PAF receptor